Cardiorentis' Heart Failure Trial Backed by $131M Investment
By Nuala Moran
Wednesday, December 5, 2012
LONDON The secretive backers of Cardiorentis Ltd. prefer to remain anonymous, but they obviously are expecting to see the name of the company's main asset, Ularitide, in lights, having made a €100 million (US$130.6 million) investment to put the product through a Phase III trial in treating 2,116 patients with acute heart failure.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.